Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison - PubMed
9 hours ago
- #Momelotinib
- #Myelofibrosis
- #Overall Survival
- Ruxolitinib is a standard first-line therapy for myelofibrosis (MF), but most patients discontinue within 5 years due to lack of response or therapy-related cytopenias.
- Momelotinib, a JAK1/JAK2/activin A receptor type 1 inhibitor, has shown benefits in reducing anemia and improving symptoms and spleen size in phase 3 trials (SIMPLIFY-1, SIMPLIFY-2, MOMENTUM).
- This study compared overall survival (OS) in ruxolitinib-experienced MF patients treated with momelotinib vs. best available therapy (BAT) using a matching-adjusted indirect comparison (MAIC).
- Results showed a favorable trend for momelotinib over BAT in both the overall population and anemic subgroup (hemoglobin < 10 g/dL), with hazard ratios < 1 across all scenarios.
- The study highlights the potential benefit of momelotinib in improving long-term outcomes post-ruxolitinib discontinuation.